Cronos Group Inc. (CRON) Earnings Call Transcript & Summary

November 7, 2022

Toronto Stock Exchange CA Health Care Pharmaceuticals earnings 45 min

Earnings Call Speaker Segments

Operator

operator
#1

Good morning, everyone. I’m Chris, and I’ll be serving as the conference operator for today. I’d like to welcome all of you to Cronos Group’s 2022 Third Quarter Earnings Conference Call. This call is being recorded today. At this point, I’ll hand things over to Shayne Laidlaw from Investor Relations. Please go ahead.

Shayne Laidlaw

executive
#2

Chris, thank you — and thanks to everyone for being here today as we go over Cronos Group's financial and business results for the third quarter of 2022. With me this morning are Mike Gorenstein, our Chairman, President and CEO, and Bob Madore, our CFO. Earlier today, Cronos Group put out a news release with our financial results, and that release has been filed on our EDGAR and SEDAR profile. That information, along with the prepared remarks, will also be posted on our website under Investor Relations. Before handing the call to Mike, I want to remind everyone that during this call we may make forward-looking statements and refer to non-GAAP financial measures. Those forward-looking statements rest on management's current expectations and assumptions, and they are subject to risks and uncertainties that could cause actual results to differ materially from what those forward-looking statements project. The factors that could cause actual results to differ materially from expectations are detailed in our earnings materials and in our SEC filings, which are available on our website, and any forward-looking statements made during this call are qualified in their entirety by those documents. Information about non-GAAP financial measures, including reconciliations to U.S. GAAP, can likewise be found in the earnings materials available on our website.

Shayne Laidlaw

executive
#3

Prepared remarks are what we'll do first, and after that we'll open things up for a question-and-answer session. So with that said, I'll hand things over to Mike Gorenstein, Chairman, President and CEO of Cronos Group.

Mike Gorenstein

executive
#4

Thanks, Shayne, and good morning to all of you. I want to begin today's call by talking about the strategic realignment that has occupied us throughout this year. As you can observe in our operating expense structure, we've taken action to reduce costs, and we keep honing our budgeting and capital allocation processes so we can improve even more. Having a leaner cost base and a more focused approach to growth across our segments helps make certain that money goes toward the right project initiatives. Every new investment carries the same objective: to grow Cronos profitably, centered on borderless products and brands capable of adapting to new markets as those markets open. Because of ongoing efforts and our strengthened startup mentality, we stay on course to achieve our target for cost savings of $20 million to $25 million in operating expenses in 2022. As we wrap up the budgeting process for '23, our attention remains sharply on trimming further costs across the business, which gives Cronos a firm footing to build its borderless product portfolio and supports long-term sustainable growth. One key focus area for us has been adapting our supply chain. Downstream processing capabilities at GrowCo are advancing through the build-out, and flower packaging is up and running. We also remain pleased with how cultivation is performing at GrowCo and at our other CMO providers.

Mike Gorenstein

executive
#5

During Q3, GrowCo reported preliminary unaudited revenue to non-Cronos customers of roughly $5.8 million. Also, keep in mind that GrowCo has been paying down its senior secured loan, which now stands at about $73 million. Those loan receivables, together with our balance sheet of roughly $890 million in cash and short-term investments, plus our strategic investments in Cronos Australia and PharmaCann, position us well to enter new markets as they open up. Managing the balance sheet through economic uncertainty is critical, and our wish to keep a substantial, industry-leading cash balance ahead of possible global strategic growth opportunities has shaped many of our decisions so far this year. To get the most out of our balance sheet, we have moved a significant share of our cash into short-term investments so we can benefit from the higher interest rate environment. Growth innovation remains a theme for us. In Canada, our Spinach brand is winning in the edible and vape categories. And we built out our offerings in these two categories with Spinach FEELZ, CBN gummy and vape products. We are excited that this portfolio of rare cannabinoids keeps growing. And with a best-in-class product development team, we believe we can keep giving consumers superior and differentiated products that use rare cannabinoids.

Mike Gorenstein

executive
#6

Expanding our portfolio by making greater use of rare cannabinoids is going to stay essential as we keep rolling out new products. We just recently announced that we had reached the equity milestone for THCV, and we're happy with how product development is advancing across our categories; we look forward to providing more information about upcoming product launches down the road. During this quarter, we also obtained findings from a significant study verified by a third party, which assessed how sustainable traditional cannabis extraction approaches are and what impact they have, alongside the company's own proprietary fermentation methods. The findings were unambiguous: the environmental footprint associated with growing the plant indoors is high, and employing innovative fermentation processes dramatically reduces the environmental impact of producing cannabinoids. These findings demonstrate a striking advantage for the fermentation method, since the average percentage carbon footprint saving achieved by fermentation is 99.8%. Although our industry is young, it is never too early to lead and to invest in technology that helps contribute to a greener future. Fermentation enabled us to make a smaller environmental impact, and it also lets us leverage rare cannabinoids, opening the door to unique and new experiences through proprietary blends of cannabinoids. Being able to create breakthrough products while also being environmentally friendly is a win-win for Cronos.

Mike Gorenstein

executive
#7

Even with a tough macro backdrop in Canada—caused by disruptions at our provincial customers in Ontario and British Columbia—our team kept rolling out new innovations and generating profitable growth. To offset those disruptions, we work hard to keep supply flowing continuously for customers. Those efforts did raise labor and shipping costs, but we believe the emphasis we placed on ensuring our products stayed on shelves will deliver returns over the long term. All of the market share commentary that follows will reference Hyfire data. Within flower, 28-gram bags now control the market, accounting for 7 of the top 10 SKUs. Spinach again held the number one ranked dry flower SKU in December, as our 28-gram wedding cake offering posted a nationwide flower market share of 6.4% in Q3, 50 basis points higher than the prior quarter, which made us the number three brand nationally in flower. Typically, 28-gram flower has a lower margin profile, notwithstanding this effect on our financials. When we sell into the provinces and build retailer relationships, having the full product portfolio they seek matters. Our 28-gram products succeed because of quality, not merely by being the cheapest.

Mike Gorenstein

executive
#8

We feel strongly that, working alongside GrowCo and our other contract manufacturing partners over the longer term, we can enhance the margin profile for this category. Turning to edibles, Spinach keeps growing its market share — up 100 basis points versus the prior quarter to 15.3%, and reaching 19.8% market share when you isolate just the gummies segment. Five Spinach gummy SKUs rank among the top 15, and that includes holding the number one and number two market share positions on a per SKU basis. We remain more efficient and targeted with how we launch SKUs in edibles, which drives share gains with only limited cannibalization — a good example being our Spinach FEELZ rare cannabinoid focused gummy additions, which are moving up the market share ranks quickly. In vapes, our market share grew 70 basis points compared with last quarter, reaching 4.1%, powered by the wave of new products we launched this year, among them the Blackberry Kush CBN vape, the Tropical Diesel CBG vape, and the Atomic Sour Grapefruit vape. In pre-rolls, even though we aren't where we'd like to be, we have a number of innovations and SKU assortment changes that we expect will alter the trajectory of this category for us. That overhaul will feature new packaging, pricing aligned with the market, and innovative new infused pre-roll offerings that shipped just last week.

Mike Gorenstein

executive
#9

The new Spinach pre-roll lineup features a THC-enhanced offering named Atomic GMO — a hybrid of Atomic Sour Grapefruit and GMO cookies, two of our top-selling flower varieties — along with the CBG-infused pre-roll sold under the new Spinach FEELZ sub brand. Getting this fresh pre-roll assortment onto retail shelves is something we're truly eager about, since it lets our sales team shine at what they do best. Moving to Israel, PEACE NATURALS keeps capturing market share. Reported net revenue from our Israeli team climbed 88% year-over-year, reaching $7 million, and adjusted for constant currency, Israeli net revenue rose 98% year-over-year to $7.4 million. Patient feedback on our latest strain introductions — Cocoa Bomba, wedding cake and GMO cookies — has been extraordinarily favorable, and so has the response to our packaging refresh, which now conveys more detail about the terpene profiles of our products. The number of patients in Israel keeps climbing too, with roughly 1,500 new medical cannabis patients added in September, bringing the total close to 120,000. That marks the third month in a row of patient gains at or above approximately 1,500. This renewed acceleration and year-over-year expansion in patient permits gives us a solid base to build on as we pursue growth opportunities in the Israeli market.

Mike Gorenstein

executive
#10

At the start of this year, our PEACE NATURALS brand ran an advertising push together with the Warriors for Life Association in Israel. That initiative urged mayors to limit or halt conventional fireworks displays, which bring distress and anxiety to medical patients as well as people living with PTSD stemming from conflict and war — a serious issue that many veterans in the country face. We take pride in having received a prestigious Clio Award for this effort in the Social Good category. Congratulations to our well-deserving PEACE NATURALS team in Israel and to the amazing work Warriors for Life does for our veterans. I'd like to spend a moment highlighting how our U.S. business is performing. As you've heard during the last couple of quarters, we've fully moved away from our beauty category focused portfolio, and all beauty focused inventory is being worked through in the wholesale and DTC channels as we redirect these brands toward adult-use products formats. We keep enhancing our cost structure in the U.S. and believe it matters to concentrate our investments solely in areas that will give us an advantage in adult-use product formats. Our focus is on building borderless products and brands that can readily be adapted to emerging cannabis markets as they turn into commercially viable opportunities.

Mike Gorenstein

executive
#11

That shift in our U.S. operations pushes us even more toward one clear goal: making adult-use cannabinoid products. As we look at the opportunity in the adult-use cannabis market, we're glad to see the progress the Biden administration made last month, issuing pardons for minor cannabis-related offenses at the federal level and encouraging governors to follow suit. Those steps are small but meaningful progress toward repairing the damage that cannabis prohibition has caused in the United States. In our view, cannabis ought to be legal, and the industry needs a comprehensive, sensible regulatory framework. With legalization efforts moving ahead across the U.S., we're committed to lending our voice to lead the industry forward in a responsible way, and we'll keep being an integral part of that conversation. We're proud to back responsible legalization efforts and meaningful social justice reform. Turning to Australia, where we hold roughly a 10% stake in Cronos Australia, that team is performing at a high level in the market's early stages of development. In our third quarter, Cronos Australia declared a $0.01 per share cash dividend, which returned about $390,000 to Cronos in October. Having a long-term, low-capital investment like Cronos Australia begin to return capital is a big positive.

Mike Gorenstein

executive
#12

Cronos Australia, too — sorry, they also just posted impressive numbers lately. Revenue for September reached a record AUD9.9 million, equal to an annualized pace of almost AUD120 million. To keep fueling growth over the long term, the company has just brought a brand-new, state-of-the-art distribution facility into operation. With infrastructure expanding, the medical market growing, and a solid team in place, we anticipate further expansion and deeper market penetration from Cronos Australia. Finally — and this certainly matters — I want to offer congratulations to Jeff Jacobson on his broader responsibilities and his promotion to Chief Growth Officer. Jeff joined Cronos back in 2016 and, most recently, held the title of SVP, Head of Growth North America. Beyond continuing to oversee marketing and sales, he will now also be responsible for North American operations in this new position. Considering how quickly this industry evolves, we think having a single leader steer things all the way from the moment an idea is born through to the product reaching the shelf will produce improved outcomes for us down the road. Congratulations again to Jeff on the new role. With that, I'll hand things over to Bob, who will walk you through our financials.

Bob Madore

executive
#13

Thanks Mike, and good morning, everyone. For the third quarter of 2022, the company reported consolidated net revenue of $20.9 million, which is a 3% increase over the third quarter of 2021. Consolidated net revenue on a constant currency basis rose 7%, reaching $21.8 million. The year-over-year revenue growth came mainly from an increase in net revenue and from the rest of the world segment, driven by cannabis flower sales in Israel and cannabis extract sales in Canada, partially offset by reuse sales in the U.S. and lower cannabis flower sales in Canada caused by adverse price mix. Consolidated gross profit for the third quarter of 2022 was $1.2 million, which represents a $1.9 million improvement from the third quarter of 2021. Gross margin was positive 6%, up from a negative 4% last year. The improvement versus prior year was mainly driven by increased revenue in the ROW segment, primarily from cannabis flower in Israel, a favorable mix of cannabis extract products that carry a higher margin profile than other product categories, and lower cannabis biomass costs, which were partially offset by lower fixed cost absorption due to the timing of the wind down activities at the PEACE NATURALS Campus and lower revenue in the U.S.

Bob Madore

executive
#14

For the third quarter of 2022, consolidated adjusted EBITDA came in at negative $21.7 million, which marks a $25.1 million improvement over the third quarter of 2021. That year-over-year gain was mainly the result of reductions in general and administrative, sales and marketing, and research and development expenses stemming from the company's strategic realignment initiative, along with better gross profit. Moving now to our segments: within the rest of the world segment, net revenue for the third quarter of 2022 totaled $20.4 million, up 11% compared with the third quarter of 2021. Constant currency net revenue in Israel rose 98% to $7.4 million, whereas constant currency net revenue in Canada declined 2% to $13.9 million. The year-over-year revenue growth came chiefly from higher flower sales in Israel and greater cannabis extract sales in Canada. Those gains were partly offset by weaker cannabis flower sales in Canada, which resulted from an unfavorable price mix shift. For the third quarter of 2022, gross profit in the rest of the world segment reached $3.1 million, an improvement of $2.6 million versus the third quarter of 2021. Gross margin was positive 15%, compared with positive 3% a year earlier. The improvement over the prior year was driven mainly by higher cannabis flower revenue in Israel, increased cannabis extract sales in Canada, which carry a higher gross margin than other product categories, and lower cannabis biomass costs, partly offset by reduced fixed cost absorption owing to the timing of wind down activities at the PEACE NATURALS Campus.

Bob Madore

executive
#15

For the rest of the world segment, adjusted EBITDA came in at negative $11.4 million in Q3 2022 — an improvement of $18.3 million compared with the third quarter of 2021. That year-over-year gain was mainly the result of lower general and administrative expenses along with higher gross profit. Now moving to the U.S. segment, net revenue for Q3 2022 was $500,000, which is a 76% drop from the third quarter of 2021. The year-over-year decline came largely from lower sales, reflecting reduced promotional spend and SKU rationalization efforts as the company carries out its realignment of the U.S. business. Gross profit in the U.S. segment for Q3 2022 was negative $2 million, a decrease of $700,000 versus the third quarter of 2021. That year-over-year decline was primarily attributable to lower sales volumes and higher inventory reserves resulting from the realignment activities. Adjusted EBITDA for the U.S. segment in Q3 2022 was negative $4.9 million, an improvement of $7.3 million from the third quarter of 2021. The prior-year comparison improved mainly because of reductions in sales and marketing, general and administrative, and research and development expenses, which were driven by the cutback in beauty category focused R&D.

Bob Madore

executive
#16

Moving on now to the balance sheet: we closed the quarter with roughly $890 million in cash and short-term investments. Foreign exchange volatility has affected our P&L, and it likewise had a sizable effect on the balance sheet. Had you applied the FX rates from the period ending December 31, 2021 to the balance sheet for the current period, cash and short-term investments would come to about $940 million — a difference of approximately $50 million. We've taken meaningful steps to cut spending and enhance our cash burn rate. Free cash flow is up more than 50% compared with the same period a year earlier, thanks to operating expense savings and a 35% decrease in CapEx, which came down to $1.6 million in the third quarter. With that, I'll hand it back to Mike.

Mike Gorenstein

executive
#17

Thanks, Bob. Canada is where we began, with the goal of learning and assembling a product portfolio without borders. The products we've launched so far keep winning, and they're driving share gains for Cronos in category after category—which gives us confidence they can succeed in any market. Even with some Canadian difficulties that weigh on profitability, demonstrating our capabilities and assembling an elite team stay at the top of our priorities. In Israel, our people keep battling for share and capturing it, and that speaks to our branding and the quality of our products. A team located on the ground is a major point of difference for us, and as that market keeps expanding and developing, you'll see us keep drawing on that advantage in Israel. As we keep carrying out our strategic realignment, it encourages me that we've sustained our momentum on innovation while running a leaner cost structure. I want to thank our committed employees, who keep their focus on the long-term plan. We are focused on one thing above all—prevailing in the adult-use cannabis market around the world—and our industry-leading balance sheet gives us the chance to invest selectively and build our platform in new markets as they open up. With that, I'll open the line for questions.

Operator

operator
#18

Thanks. <<operator_script>> Andrew Carter from Stifel has our opening question. Go ahead, your line is open.

Andrew Carter

analyst
#19

Hey, thanks, and good morning. I wanted to dig into the Spinach bags, since those have accounted for the large majority of your growth in the headset trends. Obviously, it shows some diminishing returns. First, is that profitable on a gross margin basis, and is the thinking there something like an attachment rate that lets you get the other Spinach products—whether pre-rolls or vapes—on the shelf, and this is just the cost of doing business? Thanks.

Bob Madore

executive
#20

Absolutely, Andrew. Yes, it's a positive gross margin. And I think a few things are at play here. One, we do examine it closely. From a utilization standpoint, it matters to have that kind of outflow for the supply chain, but also, when you consider utilization, for us it genuinely creates a lot of value in the GrowCo equity we hold, making certain the facility is being utilized. Beyond that, I believe it's important for the brand's strength and for some other products we're launching — building familiarity with certain new strains will definitely support some of the work we do in pre-rolls and vapes. So overall, when you look at it for the portfolio and as a value driver, it's certainly there. And I hear your point regarding 20 grams versus 3.5 grams, but I think we have to consider what consumers want and respond accordingly.

Andrew Carter

analyst
#21

Thank you. For the second question, I'd like to focus on the cost savings — the $20 million to $25 million that was achieved this year. Could you help us understand what portion of that $20 million to $25 million actually flowed through to the P&L this year? And then, how much of it becomes incremental next year? You also made reference to additional optimization savings, and I want to confirm I understood correctly that there could be more. I also recognize you noted that the U.S. is significant to your future business, but that represents $8 million in cost, if I have that right, per quarter. Is that simply a cost that will remain embedded with you until something shifts — until you reach some sort of disruptive point — or are those $8 million, or the corresponding $30 million in annualized savings, also within scope? Thanks.

Mike Gorenstein

executive
#22

Sure. So, regarding the U.S., we still see opportunity there. I wouldn't claim we're pleased with the cost structure relative to what the contribution is today. But we do see opportunity in the U.S. So it's still a business we're working on, making sure we're making it as lean as we can and basically transforming it into something that's a positive contributor. I'll let Bob speak to where we stand overall in the $25 million. But part of that, when I mention further opportunities, is just that having had the plan at the beginning of the year doesn't mean we aren't constantly looking for any incremental savings, evaluating everything we do, to find places where we can improve our bottom line.

Bob Madore

executive
#23

Yes. Thank you, Mike. I’ll add a bit more detail there. Look, we have a lot of confidence in our capacity to achieve the $20 million to $25 million in cost savings. Those represent actual realized cost savings for this fiscal year compared with the prior year. We are currently in the midst of working through our 2023 budget process, and as Mike noted in his prepared comments, we remain very focused on continuing to become more efficient and effective. Our realignment strategy and restructuring activities are genuinely going to be a major contributor to improving not only gross margin but operating efficiencies as well. So we expect additional savings beyond the 2025. We realized this year going into 2023 also.

Andrew Carter

analyst
#24

Appreciate that. I’ll make sure it gets shared.

Operator

operator
#25

Thanks. <<operator_script>> Next up, we have a question from Michael Freeman at Raymond James, whose line is now open.

Michael Freeman

analyst
#26

Morning, Mike, Bob, and Shayne — appreciate you taking our questions. It was encouraging to see the CBD-infused pre-rolls launch that involve CBN, along with product development around THCV. Could you give us an update on whether there's any fresh strategic thinking regarding how you plan to deploy cultivated cannabinoids through the Ginkgo partnership? Thanks.

Mike Gorenstein

executive
#27

Sure. Thank you. We really believe things are going well when it comes to how the product is being taken up. And much of the strategy for the product pipeline that we've had underway does lean heavily on those products. So we've seen a great response to the edibles and to the vapes, and with just shipping with a rare cannabinoid this week — sorry, last week with pre-rolls. We do feel those are the three main categories where it makes sense to have the rare cannabinoids. Now, some of the cannabinoids we've been developing that haven't been on market are starting to come out. So, just given when we look at, say, CBG field gummies having a 1.9% market share, just on a single SKU basis, we think the strategy is working, and we think the portfolio will keep gaining strength as more and more new differentiating cannabinoids come along that we can add to the roster.

Michael Freeman

analyst
#28

Alright, thanks a lot. Then, as a follow-up question: I read that your exit from PEACE NATURALS Campus is now expected to slip into 2023 — could you give us an update on that?

Mike Gorenstein

executive
#29

Sure. We still believe most of the transition ought to be finished this year, but there have been a few delays in getting certain CMOs operational so they can handle the capacity. For us, the priority is making sure we can keep products on shelf and sustain the top-line momentum, so that once the transition wraps up, we can fully capture the cost-saving benefits. That's why we're proceeding carefully and not rushing. We still expect the transition to be complete in the first half of next year, and we'd note it is definitely a gradual process, but all cultivation activities at PEACE NATURALS are now done.

Michael Freeman

analyst
#30

Alright, thanks. If you’d be willing to take just one more, when you think about your strategy for the U.S., I’m curious whether you could give some insight into how you’re thinking about it internally, particularly given that cannabis recently moved to carry out U.S. investments through a holding co—and does that shift your view on the U.S. outlook?

Mike Gorenstein

executive
#31

Yeah, I think our situation differs from that of many peers. Since we currently hold a substantial investment in PharmaCann, yet the bulk of our dry powder remains on the balance sheet. With no debt at all, we enjoy considerable flexibility. And we continue to examine it with an eye toward ensuring our product portfolio is right. And ultimately, when we consider the U.S., how do we get our product portfolio out there and how do we identify new products to add to it? We believe there is definitely a great deal of momentum behind the Biden announcement. But we are examining structures that suit us best. And I think you will see us moving closer and closer to that. So we are genuinely excited about the U.S. opportunity and we still feel it is a branded product opportunity and things will keep moving more toward the CBG looking market.

Michael Freeman

analyst
#32

That’s excellent. Thank you. I’ll make sure to share it.

Operator

operator
#33

Thanks. <<operator_script>> Vivien Azer from Cowen has our next question. Your line is open.

Vivien Azer

analyst
#34

Hello there. Thanks, and good morning. I'd like to ask a bit more about rare cannabinoids — I realize it's early days for you, Mike, but I know you keep a close eye on the U.S. market, where items highlighting rare cannabinoids can be found more readily. So I'd really appreciate hearing your thoughts on how things look from a category standpoint, and whether you believe that same dynamic will carry over to cannabis. Thank you.

Mike Gorenstein

executive
#35

That's a really good question. I think a big part of what pushed us toward this approach, or down this road, is that securing sufficient supply of certain rare cannabinoids remains quite hard. Some of them are now easy to source in the U.S. — CBG again comes to mind. But when we look at certain others, THCV for instance, you simply aren't finding commercial availability or supplies. Still, we've observed that even beyond the usual cannabis channels, cannabinoids such as CBN see substantial uptake once consumers understand what CBN does. It also delivers a different experience and works well as standalone branded products. So our view remains that this is a strong opportunity and a solid route to avoid what you might call product commoditization.

Vivien Azer

analyst
#36

Got it. As a follow-up, turning to Israel — it's good to hear the market there has picked up speed again. I'd just like an updated view on where you see market penetration heading in Israel. Thanks.

Mike Gorenstein

executive
#37

Absolutely. Yes, I believe we did experience that sort of temporary halt for a few months, and we've started to see activity resume. Things now appear to be moving in the proper direction once more. From a growth standpoint, the markets look strong. And the key item to monitor is patient growth — specifically, how much it re-accelerates toward — we just held an election last week, which we believe provides greater certainty regarding how matters will proceed politically. And we're quite optimistic. We feel that our capacity to keep outpacing market growth, along with the wholesale channel, and then also the market's continued expansion, is what gives us a promising future.

Vivien Azer

analyst
#38

I appreciate that.

Operator

operator
#39

Thank you. <<operator_script>> Our following question comes from John Zamparo at CIBC Capital Markets. Your line is now open.

John Zamparo

analyst
#40

Thanks. Morning to everyone. I'd like to bring up Israel as well. Could you speak to how pricing is behaving in that market? And in your view, are we gaining share there?

Mike Gorenstein

executive
#41

Yes, certainly. Pricing pressure has remained somewhat present, though it has eased relative to a quarter or two back. So you're witnessing part of that surplus supply making its way out of the system. And I believe we're gaining share. I think we distinguish ourselves on quality, and the brand is regarded as a leader. And we keep delivering. So I think the mix of superior quality plus, at this point, a return to patient growth is broadly enhancing the dynamic there. And I think a lesson was learned, in a sense, given that we did experience a significant shortage in Israel. So there were many efforts to bring in whatever products local companies could locate. And I think at this point there's somewhat more skepticism about which product is arriving. So we see those macro dynamics continuing to get better, and we've already observed improvement across the last couple of months.

John Zamparo

analyst
#42

All right, that's useful, thank you. My follow-up question concerns gross margin, and I apologize if I missed this. Could you tell me what that figure was, either on a consolidated basis or for the rest of world, if you exclude the PEACE NATURALS exits?

Mike Gorenstein

executive
#43

Yes. Bob, would you like to go ahead and handle that one?

Bob Madore

executive
#44

Yes. No, absolutely. We genuinely have confidence in where our emerging profile is heading. A number of positives and some negatives occurred during the quarter. But as you mentioned a moment ago, Israel's margin has stayed robust and keeps expanding as that business grows its revenues. Through our relationship and partnership with GrowCo, we're seeing reduced biomass costs. That will be a sustainable long-term type of saving, compared with history and past experience. As cannabis extracts keep becoming a larger portion of our business in Canada, favorable margin trends will continue there. Those carry higher margins than other product categories. And that was offset, especially this quarter, by a few factors. First, we realized and recorded a $1.8 million decline in gross profit dollars, sequentially from Q2 in the U.S. business. Much of that was driven by taking inventory reserves and discounting product as we work through discontinued use and product categories. In the RoW segment, we had and experienced lower fixed costs absorption this particular quarter, with the slight delay, and our transition out of the Stainer facilities, which we talked about a little bit. We also discussed on the call the adverse price mix shifts in the Canadian flower category driven by the 28 gram bags, which drove some of the margin impact in the quarter.

Bob Madore

executive
#45

And then finally, another anomaly tied to the period, we think. In the third quarter, we did some — started downstream processing of certain rare cannabinoids that haven't yet hit their efficiency milestones. But we believe getting this product to market quickly, and the differentiation it will create, is a great investment and will deliver a long-term ROI. So there are many pluses that are going to be sustained and sustainable, and many minuses. And I'd say most of the minuses we incurred in the quarter were simply period expenses. And I don't think these are things that will carry forward long-term.

Mike Gorenstein

executive
#46

Thanks, Bob. And to build on that rare cannabinoids topic, what you're seeing here — keep in mind that last year we changed the agreement so that, if we chose to commercialize the cannabinoid early, ahead of when the products launch, we'd have the option to issue one-third of the equity at commercialization. And so what's visible back there is that we were enthusiastic about the cannabinoids and wanted to bring them to market early.

John Zamparo

analyst
#47

Got it — that’s useful. Thanks.

Operator

operator
#48

Thanks. <<operator_script>> We'll take our next question from <<inaudible>> at AllianceBernstein. Your line is open.

Nadine Sarwat

analyst
#49

Hello, and thanks. Good morning, everyone. I have two questions. First, you mentioned that pre-roll innovation is expected to become your next major growth engine, and I know you specifically named those two products. Given how crowded that segment already is, why are you confident your brands will prevail there and deliver the growth you're describing? Second, your U.S. revenues keep declining, and you've explained that clearly as part of the realignment plan. Could you help us understand how to think about that segment? Over a longer horizon, should this quarter be viewed as the bottom, or is further decline ahead? How should we frame it, and when do you expect actual growth to resume? Thank you.

Mike Gorenstein

executive
#50

Thanks. On the first question — look, in cannabis, every category is either already crowded or will get crowded fast, until eventually there's differentiation and you start seeing companies separate themselves. So when we think about how we're entering, using similar approaches as in other categories, it's really about focusing on what we believe the consumer wants. It's making sure the brand performs well and that we've got a truly excellent product. So there's plenty of innovation still to come in pre-rolls. But one reason you're seeing some improvement there is that there's a chance to differentiate — being able to deliver a lot of value to consumers when it comes to the complexity of the product, with different terpenes and flavor, plus the convenience. So I think it's ultimately the same — you could have said edibles were really crowded, and I think we performed well. And I think pre-rolls is a very large category with a lot of runway and opportunity. And we're excited about it. And I think this is only the beginning. We have a lot that will be coming out over the next couple of years.

Mike Gorenstein

executive
#51

And I believe it will keep gaining share from flower. Regarding the U.S., I think that's still something you'll see in transition. What I mean is we're going to stay focused on continuing to trim things down and reach a point where we're concentrated on just the adult use product format. And then I think you'll see growth begin, and we're able to bring the right innovation back into the market and we have the infrastructure in proper shape. I think that while we would restrict the formats, in terms of product SKU, if it's something where you see the growth coming from — there are cannabinoids beyond CBD that we believe can stand out and deliver more growth. And it's very difficult to differentiate with only CBDs, similar to what we see in THC type products. So, I think being able to use a lot of different cannabinoids is what will drive growth there.

Analyst

analyst
#52

Okay, thanks.

Operator

operator
#53

Thanks. <<operator_script>> We’ll take our next question from Andrew Bond at Jefferies. Your line is open.

Andrew Bond

analyst
#54

Hi there. This is Andrew Bond speaking on behalf of Owen Bennett. We appreciate you fielding our question. I'd like to go back to what you said regarding the substantial dry powder sitting on the balance sheet and the outlook for M&A. Clearly, valuations throughout the industry have generally been declining. Could you share any additional specifics about the opportunities you may be considering and the valuation levels you're observing? Also, would you remind us of how you're focusing your thinking when it comes to deciding how that cash should be deployed? Thank you.

Mike Gorenstein

executive
#55

Absolutely. Thanks — that's a really good question. Valuations are definitely declining, I'd say. And one thing we tend to view differently here is that we're once again asking ourselves what happens in a world where state borders fall away and supply and demand reach equilibrium. So we're watching for what will stand out when you can always locate a site and you're able to go pick up products. What does that look like in a mature market? For us, it boils down to branded products. So our thinking there really hasn't changed — we're still watching to see where the best opportunities lie. And each quarter, you're seeing separation, and you're seeing that kind of maturity across a lot of the market. So we're less interested in, okay, here's a brand new market, check out the huge sizable margin spread, because you'll see that compress once you're able to bring more supply onto the market. And then over time, that begins to shift — just as in any other consumer product industry — toward whatever the best branded products are.

Andrew Bond

analyst
#56

Understood. Thanks, Mike. I’ll relay that.

Operator

operator
#57

Thanks. <<operator_script>> We'll take our next question from Matt Bottomley at Canaccord Genuity. Your line is open.

Matt Bottomley

analyst
#58

Morning, everyone. Thanks for taking the question. I’ve just got one follow-up for you, Mike, and it relates to something you said during the Q&A — that you expect many different product categories, Canada especially, to wind up saturated eventually, and I’d agree with that. Given how regulation stands today, do you believe a large share of the gains — the ones Cronos has delivered, and specifically within edibles, where a couple of your peers have shown what looks like some growth — do you think much of that improvement is sustainable? How do you see that particular category trending? Obviously dried bud dropped off sharply, most of all in the value segment. Is it your view that branded products, being as limited as they are in Canada, are somewhat more shielded from that? Looking ahead over the coming 12 months, 16 months, do you expect further pivots will be required even in the categories that are currently performing well for you?

Mike Gorenstein

executive
#59

Yes. Sorry. Let me just clear up what I was getting at there. That's a really good question. When I said saturated, what I meant is that in cannabis, just because of how big the industry is, there won't be a chance where you're the only player moving in and you can say you're one of the three companies offering pre-rolls. There's an opportunity, but you should expect everybody will chase it. Still, what I like about pre-rolls — and I'll just mention edibles briefly — is that the farther you move away from flower, the more differentiation is possible. Adding edibles is probably about as far along that differentiation curve as you can go. So pre-rolls is definitely right up there. But I don't think you'll see much change in edibles, and that's not a coincidence. If you look at the U.S., this edible is probably bigger than the category — we can see consistent brands popping up across different states, even though they aren't necessarily multi-state operators. I think you'll see that with pre-rolls. So I think more innovation is coming, outside of these gummies in Canada.

Mike Gorenstein

executive
#60

My sense is that it began in a saturated state, and if anything, what you're witnessing now is leaders coming to the fore. There's also far more stickiness here than you'd find with something along the lines of flower.

Matt Bottomley

analyst
#61

Understood — thanks.

Operator

operator
#62

Thank you. That brings the Q&A portion of today's call to a close. And with that, we'll wrap up today's conference call as well. Thanks to everyone for joining us. You're welcome to disconnect now, and we hope you have a pleasant day.

Mike Gorenstein

executive
#63

Thanks.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Cronos Group Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Cronos Group Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Cronos Group Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.